-
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
J Virol. 2000 Jan;74(2):627-43
PMID: 10623724
-
High-level expression of the human neurokinin-1 receptor in mammalian cell lines using the Semliki Forest virus expression system.
Eur J Biochem. 1994 Sep 15;224(3):917-21
PMID: 7523121
-
Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
J Virol. 2000 Jun;74(12):5716-25
PMID: 10823881
-
Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
Virology. 2000 Jun 5;271(2):350-62
PMID: 10860888
-
A trimeric structural domain of the HIV-1 transmembrane glycoprotein.
Nat Struct Biol. 1995 Dec;2(12):1075-82
PMID: 8846219
-
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
J Virol. 1996 Mar;70(3):1953-60
PMID: 8627721
-
High-level expression of G protein-coupled receptors with the aid of the Semliki Forest virus expression system.
J Recept Signal Transduct Res. 1995 Jan-Mar;15(1-4):23-32
PMID: 8903928
-
Core structure of gp41 from the HIV envelope glycoprotein.
Cell. 1997 Apr 18;89(2):263-73
PMID: 9108481
-
Atomic structure of the ectodomain from HIV-1 gp41.
Nature. 1997 May 22;387(6631):426-30
PMID: 9163431
-
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
J Virol. 1997 Oct;71(10):7198-206
PMID: 9311792
-
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
Science. 1998 Jun 19;280(5371):1884-8
PMID: 9632381
-
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
J Virol. 1998 Sep;72(9):7620-5
PMID: 9696864
-
Two-helper RNA system for production of recombinant Semliki forest virus particles.
J Virol. 1999 Feb;73(2):1092-8
PMID: 9882310
-
Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.
Vaccine. 1999 Feb 5;17(5):497-507
PMID: 10073729
-
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
J Virol. 1999 May;73(5):4009-18
PMID: 10196297
-
Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
J Gen Virol. 1999 May;80 ( Pt 5):1189-98
PMID: 10355766
-
T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.
J Med Primatol. 2004 Oct;33(5-6):251-61
PMID: 15525326
-
Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins.
Virology. 2004 Dec 5;330(1):233-48
PMID: 15527849
-
Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
Virology. 2005 Jan 5;331(1):33-46
PMID: 15582651
-
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
J Virol. 2005 Jan;79(2):771-9
PMID: 15613305
-
Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers.
Virology. 2005 Feb 5;332(1):369-83
PMID: 15661168
-
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.
J Virol. 2005 Mar;79(5):2956-63
PMID: 15709015
-
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
J Virol. 2005 Mar;79(6):3358-69
PMID: 15731230
-
Energetics of the HIV gp120-CD4 binding reaction.
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9026-31
PMID: 10922058
-
Type 1/Type 2 immunity in infectious diseases.
Clin Infect Dis. 2001 Jan;32(1):76-102
PMID: 11118387
-
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
J Virol. 2001 Jan;75(2):645-53
PMID: 11134278
-
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.
J Virol. 2001 Feb;75(3):1165-71
PMID: 11152489
-
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus.
J Infect Dis. 2001 May 1;183(9):1395-8
PMID: 11294672
-
Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.
Vaccine. 2001 May 14;19(25-26):3526-36
PMID: 11348720
-
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
J Virol. 2001 Jun;75(12):5526-40
PMID: 11356960
-
A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model.
Vaccine. 2001 Jul 16;19(28-29):3877-84
PMID: 11427261
-
Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.
Virology. 2001 Jul 5;285(2):204-17
PMID: 11437655
-
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
J Virol. 2001 Aug;75(16):7470-80
PMID: 11462019
-
Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.
J Virol. 2002 May;76(9):4634-42
PMID: 11932429
-
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.
J Virol. 2002 May;76(10):4810-21
PMID: 11967298
-
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
J Virol. 2002 Aug;76(15):7760-76
PMID: 12097589
-
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
J Virol. 2002 Sep;76(17):8875-89
PMID: 12163607
-
Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.
Vaccine. 2002 Dec 19;20 Suppl 4:A61-5
PMID: 12477430
-
Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.
J Mol Biol. 2003 Jan 10;325(2):325-35
PMID: 12488098
-
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
J Virol. 2003 Mar;77(5):3119-30
PMID: 12584337
-
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.
Nat Med. 2003 Mar;9(3):343-6
PMID: 12579198
-
Antibody neutralization and escape by HIV-1.
Nature. 2003 Mar 20;422(6929):307-12
PMID: 12646921
-
Live viral vectors: Semliki Forest virus.
Methods Mol Med. 2003;87:69-82
PMID: 12958450
-
HIV vaccine design and the neutralizing antibody problem.
Nat Immunol. 2004 Mar;5(3):233-6
PMID: 14985706
-
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
J Virol. 2004 Jul;78(14):7490-7
PMID: 15220422
-
Characterization of the conformational state and flexibility of HIV-1 glycoprotein gp120 core domain.
J Biol Chem. 2004 Jul 16;279(29):30523-30
PMID: 15131118
-
Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.
J Gen Virol. 2004 Oct;85(Pt 10):2915-24
PMID: 15448353
-
Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?
Lancet. 1985 Nov 2;2(8462):1016-7
PMID: 2865493
-
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Nature. 1990 Jun 14;345(6276):622-5
PMID: 2190095
-
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
J Virol. 1991 Feb;65(2):852-60
PMID: 1898972
-
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.
Biotechnology (N Y). 1991 Dec;9(12):1356-61
PMID: 1370252
-
Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.
AIDS Res Hum Retroviruses. 1993 Oct;9(10):963-70
PMID: 8280479
-
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
J Virol. 1994 May;68(5):3015-26
PMID: 7512157
-
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
Nat Med. 2000 Feb;6(2):207-10
PMID: 10655111